Summary Expression of the bcl-2 gene was investigated in 218 human breast carcinomas by immunohistochemical analysis. Immunodetections were assessed using (1) frozen sections, (2) documented commercially available monoclonal antibody (bcl-2/124, Dako), (3) automation of immunoperoxidase technique (Ventana) and (4) quantitative evaluation of results by image analysis (SAMBA) and statistical analysis of quantitative data (BMDP software). Bcl-2 protein expression was correlated with current prognostic indicators and with molecular markers detected by the same procedure as for Bcl-2. It was shown that Bcl-2 expression is not related to patients' age, tumour size and type or lymph node status, but an inverse relationship was observed between Bcl-2 and tumour grade (P < 0.0001). An inverse relationship was also observed between Bcl-2 expression and p53 (P<0.0001), Ki67/MIB1 antigen-(P=0.0012), and P-gp-(P=0.002) positive immunoreactions. In contrast, anti-Bcl-2 positive reaction was significantly associated with ER-positive (P < 0.001) and with ER/PR-positive or ER/PR/pS2-positive immunoreactions (P < 0.005). Bcl-2 expression was independent of CD31 and cathepsin D expression. Thus, Bcl-2 protein, thought to be antiapoptotic, exhibits parodoxical expression in human breast carcinomas. It is strongly detected in low-grade tumours (well-differentiated) with low (MIB13) growth fraction, but is independent of the tumour progression (size, node status, CD31, and cathepsin D). Bcl-2 acting on apoptosis is related to p53 gene abnormalities in breast carcinomas. Bcl-2 protein expression may also be involved in response to endocrine therapy (associated to ER/PR/pS2 positive immunoreactions) and probably with chemoresistance mechanisms (inverse relationship with P-gp).
Bcl-2 gene abnormality was first reported in non-Hodgkin's lymphomas (Tsujimoto et al, 1985) , in which t(14;18) chromosomal translocation results in an inappropriately high level of bel-2 gene expression (Korsmeyer, 1992) . The protein encoded by this gene has been shown to contribute to malignant cell expansion by prolonging cell survival (Vaux et al, 1988) and delaying or blocking programmed cell death/apoptosis (Hockenbery et al, 1990; Siegel et al, 1992) . The human Bcl-2 protein is an intracellular membrane protein with a molecular mass of 24 kDa (Chen-Levy et al, 1989 , 1990 . It resides in the nuclear envelope, endoplasmic reticulum and outer mitochondrial membranes (Krajewski et al, 1993 ) with a non-uniform distribution suggestive of participation in protein complexes (Krajewski et al, 1993) .
Apoptosis is an active form of cell death (Wyllie et al, 1987) , requiring activation of endonucleases inducing the degradation of nuclear DNA of the cell into oligonucleosome-length fragments. Apoptosis plays an important role in normal physiological conditions, but in proliferative cells and tumours it may also be the target for chemotherapeutic drugs that can kill cancer cells by activating biochemical pathways leading to programmed cell death (Eastman et al, 1990) . Drugs may act on the apoptotic process by inhibition of antiapoptotic factors up-regulated in malignant tumours. Chemoresistance may result from antiapoptotic protection from cell death and DNA fragmentation induced by antineoplastic drugs (Miyashita, , 1993 . In this regard high levels of Bcl-2 protein have been shown to protect lymphoid cells from antineoplastic drugs (Miyashita, , 1993 . In leukaemic cells, it can inhibit apoptosis induced by glucocorticoids (Alnemri et al, 1992 ) and 5-fluorodeoxyuridine or taxol (Fisher et al, 1993) . Thus, detection of this protein in tissue may be informative for monitoring the therapy of patients with cancer. However, the true significance of Bcl-2 protein expression in tumours still remains to be investigated accurately, particularly in human breast carcinomas.
In breast carcinomas a high fraction of Bcl-2-positive cells correlates with good prognostic indicators (Silvestrini et al, 1994) , longer survival in node-positive patients (Hellemans et al, 1995) , and oestrogen receptor status (ER) (Alnemri et al, 1992; Johnston et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995; Baba et al, 1996) . In addition, a highly significant relationship has been observed between the response to endocrine therapy and the presence of Bcl-2 protein in the tumour (Gee et al, 1994) . Bcl-2 protein expression has been shown to be enhanced in ER-positive tumours after tamoxifen in association with reduced cell proliferation (Johnston et al, 1994) . These results in breast carcinomas are somewhat paradoxical as it would be expected that Bcl-2 protein would counteract the tumour-inhibitory effect of endocrine therapy and that it would be down-regulated in tumours with good prognosis, with an inverse relationship with survival rates, as it is thought to prevent programmed cell death.
Only a few recent studies screening Bcl-2 protein expression in breast carcinomas have been reported (Silvestrini et al, 1994; Hellemans et al, 1995; Johnston et al, 1994; Baba et al, 1996) , and in these reports methods of investigation were different. When BCI-2 ICAs in breast cancer 341 immunohistochemistry was used to detect Bcl-2 protein in tissue sections from the tumours, samples were either fixed and paraffin embedded (Johnston et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995; Baba et al, 1996) or frozen (Gee et al, 1994) . Antibodies directed against Bcl-2 protein were also different and variably diluted. Results were evaluated by semiquantitative analysis, which relies on the observers' subjectivity, with variable and arbitrary 'cut-off' points (Johnston et al, 1994; Hellemans et al, 1995) . The rates of Bcl-2 protein-positive tumours were highly variable, ranging from 32% to 75% (Gee et al, 1994; Johnston et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995; Baba et al, 1996) . As already mentioned (Johnston et al, 1994) , validation of statistical analysis is difficult because of the lack of standardization of immunohistochemical assays and therefore practical conclusions, particularly with regard to the clinical significance of Bcl-2 expression in tissue, may not be clearly drawn from the literature survey.
In the present study, we have evaluated Bcl-2 protein expression in 218 breast carcinomas using immunohistochemical assays assessed in optimal technical conditions. Bcl-2 expression was detected (1) on frozen sections (with no risk of antigen damage owing to fixation and heating during paraffin embedding), (2) using a well-documented commercially available antibody (Dako/Bcl-2, 124), (3) by automated immunodetection (Ventana device) more reproducible than manual procedures and (4) 
MATERIAL AND METHODS

Source of tissue samples
The specimens were surgically obtained from 218 patients with breast carcinomas from January 1993 to May 1994. Mean age was 56.7 years (range 32-83 years). For all patients surgical resection was the primary treatment and none received irradiation or chemotherapy preoperatively. Surgical specimens were fixed in Bouin's fixative, paraffin embedded and stained with haematoxylin, eosin and saffronin for routine microscopic diagnosis. Samples for immunodetection were taken, by pathologists, from the representative cancerous lesions, in the same area as the sample used for the intraoperative microscopic diagnostic assessed on frozen sections. Tissue samples for immunodetections were promptly dipped in liquid nitrogen and stored frozen at -80°C in the tumour library of our laboratory.
Histopathological features
Tumour size ranged from 4 to 80 mm (mean = 16.8, s.d. = 11.95, median = 15 mm). In 90% of patients (198/218), axillary lymph node excision was performed; 62% (n = 124) were node negative and 38% (n = 75) were node positive.
Tumours were in situ in 17/218 cases (8%). Invasive ductal carcinomas accounted for 66% of cases (143/218), lobular carcinomas for 17% (38/218) and invasive carcinomas of other types for 9% (20/218).
Tumours were graded according to the Bloom grading system (SBR) (Bloom, 1957 (48/201) . Tumours were also graded according to a modified Bloom grading system (Le Doussal et al, 1989 ) into five grades: 8% of grade I, 30% of grade II, 31 % of grade III, 27% of grade IV and 4% of grade V. Tumours were also ranked according to the Nottingham prognostic index (NPI) (Galea et al, 1992) , which ranged from 2.1 to 7.3 (mean = 4.1, s.d. = 1.22).
Immunohistological staining procedures
Antibodies sources Monoclonal mouse anti-human Bcl-2 oncoprotein (Dako, bcl-2/ 124, diluted 1: 100) recognizes a peptide sequence comprising amino acids 41-54 of Bcl-2 protein (Clearly et al, 1986; Tsujimoto, 1986) . The other monoclonal antibodies used were all commercially available and used as described previously (Charpin et al, 1988 a-c; , 1995a Charpin and Pellissier, 1994 
Automated immunohistochemistry Automated immunohistochemisty (immunoperoxidase) was
performed on consecutive sections (4 gm thick) on Ventana 320 device (Grogan et al, 1993; Galaktionov et al, 1995) (Ventana Medical Systems, Tucson, AZ, USA) with Ventana kits (Ventana Medical Systems, Strasbourg, France) including also amino-ethyl carbazol reagent. Sections were counterstained with haematoxylin, dehydrated and mounted in glycergel.
Image processing and statistical analysis Immunostaining was analysed using an Axiophot microscope (Zeiss, Rueil Malmaison, France) and a 3 CCD camera (Sony, Figure 1 Immunohistochemical procedure using frozen sections, anti-Bcl-2 and 124 (Dako, 1:100) avidin-biotin-peroxidase (automated procedure/ Ventana). In invasive ductal carcinoma, the distribution of Bcl-2 protein is heterogeneous, involving not all the tumour cells and partly involving the cytoplasm adjacent to the cell membrane (Brugal et al, 1979) . The two parameters of densitometric analysis, percentage of immunostained surface (vs counterstained surface) and mean optical density (MOD), which reflects the staining intensity (SAMBA arbitrary units scale ranging from 0 to 255), were obtained as previously reported (Charpin et al, 1988 (Charpin et al, , 1995 Charpin and Pellissier, 1994 
Bcl-2 quantitative immunodetection
Among the 218 tumours probed, 171 (78%) were Bcl-2 positive and 47 were Bcl-2 negative. Distribution of anti-Bcl-2 positive staining evaluated by densitometry on tissue sections is shown on Figure 3A and B. In positive tumours the tumour surface stained by anti-Bcl-2 ranged from 3% to 70% (mean = 22.4%, s.d. = 12.1) ( Figure 3A) . The Bcl-2 quantitative immunocytochemical index (QIC) varied from 2.6 to 49.2 (mean = 15.2, s.d. = 9.8) ( Figure 3B ).
Bcl-2 expression and clinicopathological data
Bcl-2-immunostained surface evaluated by image analysis and QIC was independent of the patients' age, the tumour size, the histological type, lymph node status and the NPI.
In contrast, an inverse relationship was observed between Bcl-2 expression and tumour grades (Table 1) , with a significant ___________________ (P < 0.001) decrease in Bcl-2 expression in high-grade tumours, 30 40 50 suggesting that Bcl-2 protein is down-regulated in poorly differentiated tumours. immunoreactions with anti-p53, anti-cathepsin D, anti-CD-31 and anti-P-gp are shown in Tables 2 and 3 . A significant correlation was observed between Bcl-2 protein expression and the tumour tissue contents of ER, PR and pS2 antigens, evaluated by the same procedure on consecutive frozen sections from the same tissue blocks (Table 2 ). An inverse relationship was observed between Bcl-2 and p53 (P < 0.001) and growth fraction (MIB1/Ki67) (P < 0.0001) and P-gp (P = 0.0021) expression in tumours (Table  3) . In contrast, Bcl-2 was unrelated to CD31 (reflecting stromal angiogenesis) and to cathepsin D (tumour cell secretion of extracellular matrix protease) (Table 3) .
DISCUSSION
In these series, the Bcl-2 protein was detected in 78% of breast carcinomas by automated and quantitative immunohistochemistry using frozen samples and Bcl-2/124 MAb. In previous reports, Bcl-2 protein was detected in 32-75% of cases (Gee et al, 1994; Johnston et al, 1994; Leek et al, 1994; Nathan et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995; Baba et al, 1996) . The results obtained in these different studies cannot be compared because of variations in the methods of detection. However, detection on frozen samples avoids bias resulting from antigen damage because of fixatives, uncontrolled fixation duration or uncontrolled variations in antigen heating during paraffin embedding. Also, the results rely upon the quality of the technique (Charpin et al, 1994b) , and ideally automation provides for a better quality control (Grogan et al, 1993 (Grogan et al, , 1995 Galaktionov et al, 1995) , particularly with regard to reproducibility, in addition to the fact that many tissue samples may be identically probed at the same time.
Similarly, shortcomings may also result from semiquantitative analysis of immunostaining. Semiquantitative evaluation of results of immunodetection is very convenient, rapidly realized and is an inexpensive method of analysis. However, its reliability depends upon observer experience. Although semiquantitative analysis is sufficient to evaluate negative vs positive reactions, or very weak vs very strong immunoreactions, it is not sufficiently accurate to evaluate quantitatively intermediate patterns of staining. This must be pointed out, particularly when quantitative variations in the distribution of antigen are correlated with prognostic parameters such as survival, metastasis and recurrence or various histoprognostic indicators.
Discrepancies in the prognostic significance of Bcl-2 protein expression in major human carcinomas probably result from this type of analysis bias. In the present study we evaluated the results of Bcl-2 protein expression in tissue by computerized processing of digitized microscopic image, using the same hardware and software as in previous studies (Charpin et al, 1988 (Charpin et al, a-c, 1993 (Charpin et al, , 1994a (Charpin et al, , b), 1995a . The results were obtained more objectively, variations of staining more accurately evaluated and numerical values of parameters were more appropriate to statistical analysis (continuous variables).
We observed that Bcl-2 protein expression was greater in lowgrade than in high-grade tumours when the Bloom grading system (Bloom, 1957) or a modified system (Le Doussal et al, 1989) was employed. In these respects our results are not in agreement with those of others (Hellemans et al, 1995; Nathan et al, 1994) .
In contrast, like others (Hellemans et al, 1995) , we found no relationship between Bcl-2 protein expression and tumour size and the axillary lymph node status.
The prognostic significance of Bcl-2 expression in terms of relapse-free survival and overall survival has been evaluated in some recent studies (Nathan et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995) , using immunohistochemistry of archival fixed tissue samples, and provided discrepant results. Bcl-2 protein expression was not significantly related to a better or worse survival (disease-free survival and overall survival) in the study of Nathan et al (1994) . In contrast, in the study by Hellemans et al (1995) , although no prognostic value was demonstrated for Bcl-2 protein expression on disease-free survival and overall survival in node-negative breast cancer patients, in node-positive patients Bcl-2 expression was independently related to shortened survival (disease-free and overall survival) using multivariate analysis. In the Silvestrini et al study (1994) Bcl-2 expression in node-negative patients was related to better 6-year survival, but this predictive role of Bcl-2 protein expression was mainly dependent on p53 expression. Thus, it appears that the prognostic significance of Bcl-2 expression in breast carcinomas deserves additional investigations, in larger series, with longer follow-up, and more standardized immunohistochemical assays (work in preparation).
We compared the quantitative evaluation of Bcl-2 expression in tissue with tumour growth fraction as evaluated by MIB1 MAb. Previous reports have shown discrepant results, demonstrating a non-relationship between Ki67-positive immunoreaction and Bcl-2 protein expression (Gee et al, 1994) or an inverse relationship (Johnston et al, 1994) . In our series we also observed an inverse relationship between growth fraction and Bcl-2 expression (P < 0.0001).
In contrast, we observed no relationship between Bcl-2 expression and anti-CD-31 (Charpin et al, 1995b) or anti-cathepsin D (Charpin et al, 1993; Maudelonde et al, 1993) positive immunoreactions, suggesting that Bcl-2 involvement in the apoptotic process is independent of angiogenesis and protease synthesis, acting on extracellular matrix digestion. These results also suggest that Bcl-2 is independent of mechanisms of tumour progression.
It has been shown that the bcl-2 gene can inhibit apoptosis triggered by the wild-type p53 gene (Wang et al, 1993) . In-contrast, the mutant p53 gene can inhibit apoptosis (Lotem, 1993) although it does not seem to have the same large protective range as bcl-2 (Sachs, 1993) . An inverse correlation between the expression of Bcl-2 protein and mutant p53 was observed in the MCF 7 breast cancer cell line (Haldar et al, 1994) and in tissue sections of breast carcinomas (Baba et al, 1996; Silvestrini et al, 1994) , as in our study, suggesting that mutant p53 could substitute for bcl-2 function in breast cancer cells and that it could also down-regulate Bcl-2 expression (Haldar et al, 1994) .
We observed an inverse relationship between Bcl-2 and P-gp expression that is related to multidrug resistance. These results are also paradoxical as Bcl-2 protein has been shown to be involved in chemoresistance (Alnemri et al, 1992; Fisher et al, 1993) .
Immunostaining of steroid hormone receptors has been shown to be strongly associated with that of Bcl-2 protein (Gee et al, 1994; Johnston et al, 1994; Nathan et al, 1994; Silvestrini et al, 1994; Hellemans et al, 1995; Baba et al, 1996) , suggesting that this protein is under oestrogen regulation via oestrogen receptors (Gee et al, 1994) . In this respect, the increased expression of Bcl-2 protein in ER-positive tumours of patients treated by tamoxifen shows that Bcl-2 protein expression can be modulated by therapy with anti-oestrogens (Johnston et al, 1994) . We observed that Bcl-2 expression was significantly associated with ER-positive BCI-2 ICAs in breast cancer 345 detection in tumours (P < 0.001) and with ER+/PR+/pS2+ (P < 0.001). These results suggest that Bcl-2 protein is probably involved in the response to endocrine therapy. This is unexpected, as mentioned above, as Bcl-2 is thought to prevent programmed cell death and should counteract the tumour-inhibitory effects of endocrine therapy. Indeed, patients whose tumours have strong Bcl-2 immunostaining appear to derive the greatest benefit from endocrine therapy (Gee et al, 1994) .
The role of bcl-2 and the significance of Bcl-2 protein in breast carcinomas remains to be elucidated, in particular it remains to be seen whether Bcl-2 expression is involved directly in the pathogenesis of breast carcinomas or, alternatively, whether it is induced secondarily by other genomic changes in tumour cells responsible for modulation of Bcl-2 protein expression. Our results suggest that Bcl-2 protein is related to tumour cell differentiation (grade and hormone receptors), independent of tumour progression (node status, tumour size, stromal angiogenesis and tumour proteasic activity). The potential role of Bcl-2 expression in patient response to endocrine therapy or chemotherapy emphasizes the clinical relevance of Bcl-2 protein immunodetection in tumours. However, the use of Bcl-2 immunohistochemical assays in the monitoring of patient therapy requires optimal technical conditions of detection that can be obtained in automated and quantitative (image analysis) immunohistochemical procedures using frozen tumour samples and well-documented monoclonal antibodies.
